A novel class of therapeutic, extracellular matrix protection factor 1, has chondroprotective properties as demonstrated in a rat model of osteoarthritis
Location
Philadelphia, PA
Start Date
17-4-2026 1:30 PM
End Date
17-4-2026 2:30 PM
Description
INTRODUCTION: Osteoarthritis (OA) is a common degenerative joint disease of multifactorial etiology causing pain and disability in more than 25% of the adult population. Despite affecting a vast amount of the population, there is currently no therapy available that successfully suspends or reverses the deterioration of cartilage and bone occurring in OA. Current pharmacological treatment of OA targets inflammation and pain management through non-steroidal anti-inflammatory drugs, intra-articular corticosteroids, and analgesics. Extracellular Matrix Protection Factor 1 (ECPF-1) is a novel therapeutic that inhibits specific matrix metalloproteinases (MMPs) that are involved in degradation of the extracellular matrix (ECM) in cartilage during OA.
OBJECTIVE: In this study, a chemically-induced rat model of OA in the knee joint was utilized to investigate the effects of ECPF-1 at various concentrations in early-stage osteoarthritis.
METHODS: The progression of OA in this study was assessed using microcomputed tomography (µCT), histological analysis and gait analysis. The acute effects of OA progression were studied on a timeline of 4 and 8 weeks.
RESULTS: The µCT data showed that at both the 4-week post-loading (4 weekly injections of ECPF-1(0.25uM – 5uM), saline control or Bone Morphogenetic Protein-7 (500 ng) control) and 8-week protection-extension phases, the ECPF-1 treated cohort demonstrated decreased ECM degradation compared to untreated controls. Improved articular cartilage histological staining of the ECPF-1 treated joints supported the µCT image data for the femur and tibia, while rat gait was improved. Trabecular thickness and number were increased following ECPF-1 treatment.
CONCLUSION: These results suggest a chondroprotective property to ECPF-1 and its potential as a therapeutic that may slow the progression of OA.
Embargo Period
5-21-2026
A novel class of therapeutic, extracellular matrix protection factor 1, has chondroprotective properties as demonstrated in a rat model of osteoarthritis
Philadelphia, PA
INTRODUCTION: Osteoarthritis (OA) is a common degenerative joint disease of multifactorial etiology causing pain and disability in more than 25% of the adult population. Despite affecting a vast amount of the population, there is currently no therapy available that successfully suspends or reverses the deterioration of cartilage and bone occurring in OA. Current pharmacological treatment of OA targets inflammation and pain management through non-steroidal anti-inflammatory drugs, intra-articular corticosteroids, and analgesics. Extracellular Matrix Protection Factor 1 (ECPF-1) is a novel therapeutic that inhibits specific matrix metalloproteinases (MMPs) that are involved in degradation of the extracellular matrix (ECM) in cartilage during OA.
OBJECTIVE: In this study, a chemically-induced rat model of OA in the knee joint was utilized to investigate the effects of ECPF-1 at various concentrations in early-stage osteoarthritis.
METHODS: The progression of OA in this study was assessed using microcomputed tomography (µCT), histological analysis and gait analysis. The acute effects of OA progression were studied on a timeline of 4 and 8 weeks.
RESULTS: The µCT data showed that at both the 4-week post-loading (4 weekly injections of ECPF-1(0.25uM – 5uM), saline control or Bone Morphogenetic Protein-7 (500 ng) control) and 8-week protection-extension phases, the ECPF-1 treated cohort demonstrated decreased ECM degradation compared to untreated controls. Improved articular cartilage histological staining of the ECPF-1 treated joints supported the µCT image data for the femur and tibia, while rat gait was improved. Trabecular thickness and number were increased following ECPF-1 treatment.
CONCLUSION: These results suggest a chondroprotective property to ECPF-1 and its potential as a therapeutic that may slow the progression of OA.